
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
2
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
3
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
4
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
5